key: cord-0732506-cw6mfjsw
authors: Athar, Iqra
title: “Cerebral venous sinus thrombosis sequel of COVID Encephalitis; a rare presentation”
date: 2021-07-16
journal: Brain Hemorrhages
DOI: 10.1016/j.hest.2021.07.003
sha: 842b9125be36ad0489f44688298f75c6b4ad63ac
doc_id: 732506
cord_uid: cw6mfjsw

The SARS Covid-19 pneumonia became a pandemic in 2019 affecting millions worldwide and carried a significant high mortality rate. The common presentation of this novel virus is upper and lower respiratory tract infection. However, its popularity as neuropathogen has increased dramatically. Patient presents a wide range of symptoms. We report a case of Covid-19 encephalitis which was incidentally found to have cerebral venous sinus thrombosis, presented with acute delirium and then developed new onset seizures.

syndrome (ARDS), thromboembolic syndrome, severe metabolic syndromes, severe acute tubular necrosis, electrolyte abnormalities, neurologic syndromes and cardiac events, including myocarditis and arrhythmias. [1] [2] [3] COVID-19 possesses neuroinvasive potentials, which makes the central nervous system (CNS) an important target. [4] Cerebral venous sinus thrombosis (CVST) is an uncommon condition and can occur as a result of various genetic or acquired risk factors. Infections are one of the most important etiological factors in development of cerebral venous sinus thrombosis. Neurological manifestation of COVID-19, encephalitis and thrombotic event CVST have been progressively appreciated.

A 30 years old gentle\man presented with history of acute delirium and on arrival developed generalized tonic-clonic seizures. He has history of body aches and fever one week prior to presentation. There was no history of hypertension, diabetes mellitus or drug intoxication.

His presenting GCS was 12/15 (E3, M5, V3). On examination he was afebrile, there were no signs of meningeal irritation. There was no focal deficit and cranial nerve examination was also unremarkable.

The initial laboratory testing including hematology, biochemistry and coagulation profile was normal. CT-Brain without contrast was unremarkable. As patient has history of prior fever and body aches, COVID-PCR was sent immediately (reporting takes 2-3 days). Lumbar puncture was performed and management started on lines of viral encephalitis i.e. IV fluids and antiepileptic were given along with IV acyclovir which was started empirically. Cerebral spinal fluid (CSF) showed WBC 19, mainly lymphocytic 95%, protein 92.8 (<45), Glucose 64.2 (40-70) BSR 110mg/dL. CSF for gram staining and AFB staining was negative and no growth was obtained on culture. Patient's GCS improved to 15/15 and seizures were controlled within 48 hours after the initiation of therapy.

Meanwhile MRI-brain with contrast was done (on 4 th day of admission) which showed partial thrombi of superior sagittal sinus, vein of Galen, bilateral transverse sinus and left proximal sigmoid sinus, sequel of COVID-19. (FIGURES 1-2). He was immediately put on oral anticoagulation, Rivaroxiban 15mg in morning and evening dose for 21 days followed by 20mg for 3 months. Before starting anticoagulation thrombophilia, workup was sent. Thrombophilia work up including Lupus anticoagulation, Factor -V Leiden, Anti thrombin III, Protein C and S stands negative (TABLE 2) . Later his COVID-PCR nasal swab came out positive and PCR for HSV I and II was not detected in CSF sample.

With the progression of COVID-19, reports of neurological manifestations are increasing. These manifestations can be associated as direct effects of the virus on the nervous system, para-infectious or post-infectious immune-mediated disease, and neurological complications of the systemic effects of COVID-19. Over a 3-week period, [5] 39 (31%) patients had altered mental status, which included 16 (13%) with encephalopathy (of whom seven [6%] had encephalitis), and 23 (18%) with a neuropsychiatric diagnosis, including ten (8%) with psychosis, six (5%) with neurocognitive (dementia-like) syndrome, and four (3%) with an affective disorder. Notably, 77 (62%) patients had a cerebrovascular event: 57 (46%) ischemic strokes, nine (7%) intracerebral hemorrhages, and one (<1%) CNS vasculitis, and ten (8%) other cerebrovascular events are seen in one registry. [5] The main concern for SARS-CoV-2 infection concern the routes of entry into the nervous system and the relative contribution of viral infection versus host response to the subsequent damage as with other neurotropic viruses.

One possible mechanism is viral entry to the brain through the olfactory bulb-the only part of the CNS not protected by Dura-could be one conceivable route for SARS-CoV-2, especially given the anosmia in COVID-19. [6] This entry route is thought to be used by the herpes simplex virus, the most common cause of sporadic viral encephalitis. [7] Alternative entry routes include carriage across the blood-brain barrier, following viraemia, or through infected leukocytes. [8] The angiotensin converting enzyme 2 receptor, to which SARS-CoV-2 binds for entry into cells, [9] is found in brain vascular endothelium and smooth muscle. [10] SARS-CoV-2 replicates in neuronal cells in vitro. [11] . One proposed criterion for diagnosis of encephalitis is given in (TABLE 1) according to which our patient falls in probable criteria.

The treatment of COVID-19-related encephalitis is mainly supportive. A variety of treatments, including high-dose IV steroids, IV immunoglobulin, and immunomodulators (e.g., rituximab), have been tried in various cases, with somewhat limited outcomes. [17] CVST is an uncommon condition. There are several cases reported in literature of CVST and COVID 19.

It has several risk factors including genetic and acquired. CVST has a favorable prognosis if diagnosed and treated early. SARS-CoV-2 is known to produce a thrombophilic state. Early indicators suggest that cerebrovascular disease in COVID-19 might be due to a coagulopathy. SARS-CoV-2 can cause damage to endothelial cells, activating inflammatory and thrombotic pathways. [9] Endothelial cell infection or monocyte activation, up regulation of tissue factors, and the release of micro particles, which activate the thrombotic pathway and cause microangiopathy, might occur for SARS-CoV-2 as for other viruses. [12] [13] Monocyte activation is postulated to constitute part of the secondary haem phagocytic lymphohistiocytosis described in severe COVID-19. [14] Thrombocytopenia with elevated D-dimer and Creactive protein in severe COVID-19 and stroke are consistent with a virus-associated micro angiopathic process. [15] Endothelial dysfunction can potentially lead to microvascular and macrovascular complications in the brain, as described systemically. [16] Our patient presented with neurological symptoms rather than with usual respiratory symptoms. He had a history of self-limited symptoms of fever and cough 1 week earlier. He responded to the initial empirical treatment of encephalitis and later was incidentally found to have CVST on further workup. CVST has either occurred as a direct effect of COVID-19 infection or has occurred secondary to COVID -19 encephalitis. To date, no case report has shown occurrence of CVST secondary to COVID-19 encephalitis which makes our case report unique.

Nevertheless, in the COVID-19 pandemic era, a high index of suspicion of encephalitis and CVST should be considered, particularly in patients with headache, acute delirium, seizures, focal deficit; whether they present with respiratory symptoms of SARS-CoV-2 infection or not. [18] Confirmed:

(1) SARS-CoV-2 detected in CSF or brain tissue † or evidence of SARS-CoV-2-specific intrathecal antibody; and

(2) no other explanatory pathogen or cause found • the new onset of either cough, fever, muscle aches, loss of smell, or loss of taste;

• lymphopenia or raised D-dimer level;

• and radiological evidence of abnormalities consistent with infection or inflammation (ground glass changes) † Detection in CSF or brain tissue by PCR, culture, or immunohistochemistry, as appropriate. ‡ Detection in non-CNS sample by PCR or culture. § Serological evidence of acute infection can be defined as detection of IgM, IgG seroconversion, or an increase of four times in antibody titers in paired acute and convalescent serum samples. It is not inaccurate to express that COVID-19 has the wide range of central and peripheral nervous system associations, although primarily it is known to involve respiratory system; that brings attention to our case report.

Encephalitis is more frequently seen in viral infections. However, hypercoagulable states and cerebrovascular disease, which have been seen rarely for some acute viral infections, either as part of encephalitis or direct association with virus are an important neurological complication of COVID-19.

Majority of neurological complications, particularly encephalitis and stroke, has long term effects. It has significantly increased lifelong patient morbidity as well as burden on health care system so prompt diagnosis and management can reduce patient's lifelong disability to a great extent.

Clinical features of Covid-19 in elderly patient: a comparison with young and middle age patients

central nervous system infection by SARS coronavirus. Emerg Infect Dis

Central nerveous system involvement after the infection with COVID-19 and other coronaviruses

Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19

UK-wide surveillance of neurological and neuropsychiatric complications of COVID-19: the first 153 patients

Perlman SSevere acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Donaghy M Brain's diseases of the nervous system. 12th edn

Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?

Zhou QStructural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

Viral-associated thrombotic microangiopathies

How viruses contribute to the pathogenesis of hemophagocytic lymphohistiocytosis

COVID-19: consider cytokine storm syndromes and immunosuppression

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

SARS-CoV-2 associated acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year old woman without comorbidities: a case report

Neurological associations of COVID-19. The Lancet Neurology